2022年欧洲肿瘤内科学会（ESMO）BC大会将于5月3~5日（当地时间）正式召开，会上将报告转化研究、新药、分子和功能诊断、生物标志物以及临床研究中的前沿研究，提供所有改变临床实践新数据的全面概述，并确保其具有清晰的临床诊疗路线图。日前，会议已经正式公布日程，【肿瘤资讯】为您整理了相关“Poster Display session”专场中国学者报告主题内容。话不多说，让我们看看ESMO BC会议，有哪些值得关注的“中国之声”呢？
7P - 深度学习RNA修饰模型预测乳腺癌患者无病生存期的开发和验证
题目：Development and Validation of a Deep Learning RNA Modification Model Predict Disease-free Survival in Patients with Breast Cancer
作者：Y. Yu1, Q. Ou2, C. Yu2, L. Wang2, R. Zhang2, R. Zhao2, B. Qu2, Z. Wang2, R. Lin2, H. Yao2,1Guangzhou/CN, 2Guangdong/CN
13P - 乳腺癌三级淋巴结构的临床病理和预后意义：系统综述和荟萃分析
题目：Clinicopathological and Prognostic Significance of Tertiary Lymphoid Structures in Breast Cancer: A Systemic Review and Meta-Analysis
作者：B. Wang, Y. Jiang, Chengdu/CN
16P –评估血浆HER2水平的早期变化有助于预测晚期乳腺癌的治疗反应：一项多中心、前瞻性、非干预性临床研究
题目：Assessing early changes in plasma HER2 levels is useful for predicting therapeutic response in advanced breast cancer: A multicenter, prospective, noninterventional clinical study
作者：Y.-K. Kang, P. Yuan, Beijing/CN
23P - 多维体内CRISPR筛选确定Lgals2作为三阴性乳腺癌免疫治疗靶点
题目：In Vivo Multi-Dimensional CRISPR Screens Identify Lgals2 as an Immunotherapy Target in Triple-Negative Breast Cancer
作者：P. Ji, Y. Gong, M. Jin, X. Hu, G. Di, Z. Shao, Shanghai/CN
72P - FISH检测HER2/CEP17比值在HER2阳性早期乳腺癌中的预后价值乳腺癌中的预后价值
题目：Prognostic value of HER2/CEP17 ratio in HER2-positive early breast cancer by FISH testing
作者：F. Zheng, F. Du, P. Yuan, Beijing/CN
116P - 通过稳健优化和手动闪光方法对乳腺癌放疗中VMAT的稳健性评价
题目：Robustness evaluation of VMAT by robust optimization and manual flashapproach for breast cancer radiotherapy
作者：H.M. Hung, W.S. Leung, Hong Kong/HK
118P - CD146与整合素1相互作用激活LATS1-YAP信号并激发乳腺癌细胞的抗辐射能力
题目： CD146 interaction with integrin _1 activates LATS1-YAP signaling and provokes the radiation-resistance in breast cancer cells
作者：L. Yuanke, D. Zeng, H. Lin, Shantou/CN
128P - 容积弧形调强放射治疗在左乳癌中的作用
题目：The role of volumetric modulated arc therapy in left breast cancer
作者：E.Y.W. Cheung, Kowloon/HK
138P - 骨密度与乳腺癌风险：一项队列研究和孟德尔随机化分析
题目：Bone mineral density and risk of breast cancer: a cohort study and Mendelian randomization analysis
作者：Y. Zhang1, X. Yu1, X. Huang1, W. He2, H. Yang1, X. Mao3, 1Fuzhou/CN, 2Hangzhou/CN,3Huddinge/SE
201P - 年龄 > 35岁的女性中，新发与复发乳腺癌的转移和生存特征：一项基于医院人群的全国多中心研究
题目：Metastatic and survival characteristics of de novo versus replased breast cancer in female aged>35-year-old: A nationwide multicenter study based onhospital population.
作者：J. Zhang, J. Wang, J. Fan, B. Xu, Y. Qiao, Beijing/CN
具体专场日程请点击下方网址：
2022 ESMO BC “Poster Display session”日程
排版编辑：肿瘤资讯-Jo
苏公网安备32059002004080号
